A New Era in Oncology

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTideTM technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.

Our highly experienced management team has a successful track record of building global, integrated biopharmaceutical companies and bringing life-saving oncology therapeutics to patients.

What's happening...

NuCana Logo

AACR Annual Meeting 2020

June 22 - 24, 2020
Virtual Meeting II, Sessions Available Online

NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020

Our Values

MISSION: To Transform Chemotherapy and Pioneer a New Era in Oncology

"Utilising our proprietary ProTide technology platform we are developing new medicines designed to overcome key cancer resistance mechanisms and improve the survival outcomes for patients."

Hugh S. Griffith

Founder & CEO
Hugh Griffith

ACELARIN
(NUC-1031)

Designed to overcome the key cancer resistance mechanisms associated with gemcitabine. Currently in a Phase III study for patients with biliary tract cancer.

NUC-3373

Designed to overcome the limitations associated with 5-FU. Currently being investigated in patients with advanced colorectal cancer.

NUC-7738

A transformation of 3’-dexoxyadenosine, a novel nucleoside analog with a unique anti-cancer modes of action. Currently in a Phase I study.

NEW GENERATION
ANTI-CANCER AGENTS

NuCana's ProTide technology is a powerful platform generating new anti-cancer medicines designed to overcome the key cancer resistance mechanisms.

NUCANA'S
PIPELINE

We take a scientifically driven approach to designing ProTides, which we believe have the potential to provide highly efficacious cancer therapies with improved tolerability.

LATEST
NEWS

NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic

Leadership

Meet Our Executive Team

Hugh Griffith

Hugh Griffith

Chief Executive Officer

Christopher Wood

Christopher Wood

Chief Medical Officer

San Francisco

Don Munoz

Chief Financial Officer

What's happening...

Jefferies logo

Virtual: June 2020

NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference

Wednesday, June 3, 2020

Global Headquarters

3 Lochside Way
Edinburgh
EH12 9DT
United Kingdom

Telephone: +44 (0)131 357 1111

E-mail: info@nucana.com

U.S. Office

275 Grove Street
Newton, MA 02466

Telephone: +1 617 663 4821

E-mail:info@nucana.com

Contact us